Form 10-Q ACELYRIN, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Acelyrin Inc (SLRN) PT Lowered to $6 at Citi
August 14, 2024 9:25 AM EDTCiti analyst Samantha Semenkow lowered the price target on Acelyrin Inc (NASDAQ: SLRN) to $6.00 (from $8.00) while maintaining a Neutral rating.
The analyst comments "Acelyrin announced a strategic reprioritization to focus resources on development of lonigutamab (anti-IGFR1) in thyroid eye disease. The company will... More
